- The Beinao No.1 system uses a semi-invasive epidural approach with 128-channel signal acquisition and sub-100ms motion-intent decoding.
- China’s drug regulator approved the world’s first invasive BCI device for commercial use in March 2026, signaling full-scale industry growth.
- Beijing Tiantan Hospital is positioning itself as China’s central BCI hub, with experts forecasting public deployment within three to five years.
On April 15, 2026, China successfully completed its first live-streamed brain-computer interface (BCI) implantation surgery using the domestically-developed “Beinao No.1” system at Beijing Tiantan Hospital.
According to CGTN, the procedure was broadcast in 4K to hundreds of experts attending a national BCI clinical application conference, marking a significant step toward large-scale clinical validation of advanced BCI technology in the country.
The surgery involved placing a coin-sized implant precisely outside the patient’s dura mater through a minimally invasive cranial opening. As reported by China Daily, the patient was a young man who became paralyzed after an electric scooter accident, with hand-function training scheduled to begin two weeks post-operation.
Beinao No.1 Technical Breakthrough
The Beinao No.1 system represents a semi-invasive approach that achieves an internationally recognized optimal balance between signal accuracy and safety. The device features 128-channel synchronous signal acquisition with a 30 kHz high-frequency sampling rate, enabling motion-intent decoding in under 100 milliseconds. CGTN reported that the system utilizes wireless data transmission and charging, eliminating external wires penetrating the skin. The epidural implantation technique avoids opening the dura mater or making direct contact with brain tissue, significantly reducing surgical risks and infection potential compared to fully invasive alternatives.
According to Reuters, China’s National Medical Products Administration approved the world’s first invasive BCI medical device for commercial use in March 2026, with BCI products designated as “future industry” in Beijing’s latest five-year plan. The semi-invasive approach allows patients to avoid prolonged hospitalization and instead carry out high-quality neurorehabilitation training at home, potentially transforming how neurological rehabilitation is conducted nationwide.
So, about that livestream—surgeons performing brain surgery while hundreds of experts watch in real-time via 4K broadcast, offering simultaneous academic commentary. China Daily noted this approach reflects the medical community’s transparency and confidence in the technology. One has to appreciate the audacity of turning a neurosurgical procedure into a broadcast event, complete with Q&A segments between incision and implant placement. It’s either a bold statement in clinical transparency or an elaborate form of medical theater designed to impress investors and regulators alike.
China Races to Compete in BCI Development
China’s BCI sector is experiencing rapid acceleration from research toward commercialization, with leading experts predicting the technology could move into practical public use within three to five years. According to Reuters, the country is racing to catch up with U.S. competitors including Elon Musk’s Neuralink, which has already conducted multiple human implantations. Beijing Tiantan Hospital established China’s first domestic BCI clinical and translational ward in June 2025 and has completed multiple Beinao No.1 implantations, positioning the hospital as a central hub in the nation’s BCI development strategy.
The strategic importance of BCI technology extends beyond healthcare. CGTN reported that China’s brain-computer interface industry is entering a new phase of development as the country accelerates efforts to translate research into commercial products. The Beinao No.1 surgery demonstrates China’s full-chain independent research and development capabilities, showcasing domestic innovation in a technology sector that could define neurological treatment paradigms for decades to come.
Meanwhile, somewhere in Silicon Valley, a tech executive is probably asking their BCI team why China keeps getting these “world’s first” headlines. China’s BCI industry is rapidly scaling from research to commercialization, driven by strong policy support and regulatory prioritization. The question is no longer whether brain-computer interfaces will become mainstream medical technology, but which nation will dominate the market when they do—and based on the pace of announcements coming out of Beijing, the answer might be settling itself sooner than expected.
